A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100

Status
Active
Cancer Type
Prostate Cancer
Trial Phase
Phase III
Eligibility
18 and over, Male
Study Type
Treatment
NCD ID
NCT01605227
Protocol IDs
XL184-307 (primary)
2012-001834-33
Study Sponsor
Exelixis, Incorporated

Summary

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.